In This Article:
As the U.S. stock market faces a turbulent period with major indices like the Dow Jones and S&P 500 on track for their worst week in two years, concerns about tariffs and economic health continue to dominate investor sentiment. In such uncertain times, identifying stocks that are trading below their intrinsic value can offer potential opportunities for investors looking to navigate these challenging conditions.
Top 10 Undervalued Stocks Based On Cash Flows In The United States
Name | Current Price | Fair Value (Est) | Discount (Est) |
Brookline Bancorp (NasdaqGS:BRKL) | $11.08 | $21.98 | 49.6% |
Atour Lifestyle Holdings (NasdaqGS:ATAT) | $30.59 | $60.31 | 49.3% |
Dime Community Bancshares (NasdaqGS:DCOM) | $28.74 | $56.26 | 48.9% |
Gilead Sciences (NasdaqGS:GILD) | $116.04 | $229.16 | 49.4% |
Brunswick (NYSE:BC) | $58.75 | $114.71 | 48.8% |
Live Oak Bancshares (NYSE:LOB) | $29.55 | $58.73 | 49.7% |
Five9 (NasdaqGM:FIVN) | $32.89 | $65.55 | 49.8% |
JBT Marel (NYSE:JBTM) | $131.07 | $260.21 | 49.6% |
Albemarle (NYSE:ALB) | $76.48 | $150.46 | 49.2% |
TransMedics Group (NasdaqGM:TMDX) | $65.29 | $129.23 | 49.5% |
Let's explore several standout options from the results in the screener.
Ligand Pharmaceuticals
Overview: Ligand Pharmaceuticals Incorporated is a biopharmaceutical company focused on developing and licensing biopharmaceutical assets globally, with a market cap of approximately $2.22 billion.
Operations: The company's revenue segment is primarily derived from the development and licensing of biopharmaceutical assets, totaling $167.13 million.
Estimated Discount To Fair Value: 47.5%
Ligand Pharmaceuticals is trading significantly below its fair value estimate of US$220.76, with a current price of US$116, suggesting it may be undervalued based on cash flows. Despite recent financial challenges, including a net loss of US$4.03 million for 2024 and substantial insider selling, the company expects revenue growth between US$180 million to US$200 million in 2025. Analysts forecast profitability within three years, indicating potential future value realization.
CNX Resources
Overview: CNX Resources Corporation is an independent natural gas and midstream company focused on acquiring, exploring, developing, and producing natural gas properties in the Appalachian Basin with a market cap of approximately $4.41 billion.
Operations: The company's revenue segments include Shale, generating approximately $1.15 billion, and Coalbed Methane, contributing $105.12 million.